James Watters
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Eosinophilic Disorders and Syndromes, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies
Most-Cited Works
- → Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors(2012)314 cited
- → EMT is the dominant program in human colon cancer(2011)278 cited
- → MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts(2011)275 cited
- → Comparative expression pathway analysis of human and canine mammary tumors(2009)192 cited
- → Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System(2009)173 cited
- → A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors(2010)152 cited
- → Genome-wide discovery of loci influencing chemotherapy cytotoxicity(2004)144 cited
- → Cancer pharmacogenomics: current and future applications(2003)140 cited
- → RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations(2023)106 cited
- → TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma(2016)92 cited